TY - JOUR
T1 - Management of gynaecomastia in patients with prostate cancer
T2 - A systematic review
AU - Di Lorenzo, Giuseppe
AU - Autorino, Riccardo
AU - Perdonà, Sisto
AU - De Placido, Sabino
PY - 2005/12
Y1 - 2005/12
N2 - Patients with prostate cancer are increasingly being offered treatment with non-steroidal antiandrogen monotherapy, which offers potential quality-of-life benefits compared with other treatment. Non-steroidal antiandrogens directly antagonise androgen action in breast tissue, and indirectly increase the oestrogen concentration. Thus, the most troublesome side-effects of monotherapy with these drugs are gynaecomastia and breast pain. Patients younger than 60 years of age, who might not have symptoms of prostate cancer, are probably more concerned about their body image and the development of enlarged breasts than are those older than 60 years. Clinicians who seek a treatment for prostate cancer need information on simple and well-tolerated options for the management of gynaecomastia and breast pain. In this review, management options for gynaecomastia caused by hormonal manipulation in patients with prostate cancer are discussed.
AB - Patients with prostate cancer are increasingly being offered treatment with non-steroidal antiandrogen monotherapy, which offers potential quality-of-life benefits compared with other treatment. Non-steroidal antiandrogens directly antagonise androgen action in breast tissue, and indirectly increase the oestrogen concentration. Thus, the most troublesome side-effects of monotherapy with these drugs are gynaecomastia and breast pain. Patients younger than 60 years of age, who might not have symptoms of prostate cancer, are probably more concerned about their body image and the development of enlarged breasts than are those older than 60 years. Clinicians who seek a treatment for prostate cancer need information on simple and well-tolerated options for the management of gynaecomastia and breast pain. In this review, management options for gynaecomastia caused by hormonal manipulation in patients with prostate cancer are discussed.
UR - http://www.scopus.com/inward/record.url?scp=28044452182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28044452182&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(05)70464-2
DO - 10.1016/S1470-2045(05)70464-2
M3 - Article
C2 - 16321765
AN - SCOPUS:28044452182
VL - 6
SP - 972
EP - 979
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 12
ER -